Docoh
Loading...

ATRA Atara Biotherapeutics

Filed: 4 May 21, 4:07pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2021

 

Atara Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-36548

 

46-0920988

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

611 Gateway Boulevard, Suite 900 South San Francisco, CA

 

 

 

94080

(Address of Principal Executive Offices)

 

 

 

(Zip Code)

 

Registrant’s telephone number, including area code: (650) 278-8930

(Former Name or Former Address, if Changed Since Last Report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities pursuant to Section 12 (b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

 

ATRA

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 


 

 

Item 2.02

Results of Operations and Financial Condition

On May 4, 2021, Atara Biotherapeutics, Inc. (“Atara”) announced certain financial results for the first quarter ended March 31, 2021. A copy of Atara’s press release, titled “Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress” is furnished as Exhibit 99.1 hereto.

Item 9.01

Financial Statements and Exhibits

 

(d)

Exhibits.

 

Exhibit No.

 

Description

 

 

99.1

 

Press Release, dated May 4, 2021

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this report and the attached Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ATARA BIOTHERAPEUTICS, INC.

 

 

 

Date: May 4, 2021

 

By:

/s/ Utpal Koppikar

 

 

 

Utpal Koppikar

 

 

 

Chief Financial Officer